Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans

Pharmacogenomics Journal

Volumn 8, Issue 1, 2008, Pages 53-60

  Kimmel, S E ^a   Christie, J ^a   Kealey, C ^a   Chen, Z ^a   Price, M ^a   Thorn, C F ^b   Brensinger, C M ^a   Newcomb, C W ^a   Whitehead, A S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APOLIPOPROTEIN E; CHYLOMICRON; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; OXIDOREDUCTASE; VITAMIN K GROUP; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIVER CLEARANCE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE;

AFRICAN AMERICANS; AGED; ANALYSIS OF VARIANCE; ANTICOAGULANTS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VARIATION (GENETICS); WARFARIN;

EID: 38349098717     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500445     Document Type: Article

References (25)

1. Breckenridge AM. Interindividual differences in the response to oral anticoagulants. Drugs 1977; 14: 367-375.
2. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
3. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006, 16: 101-110.
4. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
5. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
6. Majerus PW, Broze Jr GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill: New York, 1996, pp. 1341-1359.
7. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr 1998; 67: 1226-1231.
8. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999; 63 301-310.
9. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 1987; 80: 1571-1577.
10. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J Nutr 1996; 126: 1192S-1196S.
11. Saupe J, Shearer MJ, Kohlmeier M. Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 1993; 58: 204-208.
12. Kohlmeier M, Saupe J, Drossel HJ, Shearer MJ. Variation of phylloquinone (Vitamin K1) concentrations in hemodialysis patients. Thromb Haemost 1995; 74: 1252-1254.
13. Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM et al. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Geno 2005; 15: 69-74.
14. Kohnke H, Sorlin K, Granath G. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 2005; 61: 381-388.
15. Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol 2005; 61: 781-783.
16. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics 2006; 16: 609-611.
17. Kohlmeier M, Saupe A, Saupe J. Anticoagulant response to phenprocoumon is related to apolipoprotein E genotype. Klin Lab 1995; 41: 359-361.
18. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649.
19. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
20. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-185.
21. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993; 2: 159-163.
22. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 1993; 121: 598-602.
23. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
24. Box GEP, Cox DR. An analysis of transformations. J Royal Stat Soc 1964; B-26: 211-252.
25. Draper NR, Smith H. Applied Regression Analysis. Second ed. John Wiley & Sons Inc.: New York, 1981.